GeoVax Labs (GOVX) 10-K 9 Mar 22 2021 FY Annual report Financial data

Document And Entity Information

Document And Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2021	Mar. 09, 2022	Jun. 30, 2021
Document Information [Line Items]
Entity Central Index Key	0000832489
Entity Registrant Name	GeoVax Labs, Inc.
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2021
Document Type	10-K
Document Annual Report	true
Document Period End Date	Dec. 31, 2021
Document Transition Report	false
Entity File Number	001-39563
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	1900 Lake Park Drive, Suite 380
Entity Address, City or Town	Smyrna
Entity Address, State or Province	GA
Entity Tax Identification Number	87-0455038
Entity Address, Postal Zip Code	30080
City Area Code	678
Local Phone Number	384-7220
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Public Float			$ 30,365,310
Entity Common Stock, Shares Outstanding		7,089,025
Auditor Name	WIPFLI LLP
Auditor Location	Atlanta, Georgia
Auditor Firm ID	344
ICFR Auditor Attestation Flag	false
Warrant [Member]
Document Information [Line Items]
Title of 12(b) Security	Warrants to Purchase Common Stock
Trading Symbol	GOVXW
Security Exchange Name	NASDAQ
Common Stock [Member]
Document Information [Line Items]
Title of 12(b) Security	Common Stock $0.001 par value
Trading Symbol	GOVX
Security Exchange Name	NASDAQ

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Dec. 31, 2021	Dec. 31, 2020
ASSETS
Cash and cash equivalents	$ 11,423,870	$ 9,883,796
Grant funds and other receivables	49,006	182,663
Prepaid expenses and other current assets	156,240	168,689
Total current assets	11,629,116	10,235,148
Property and equipment, net	156,938	147,741
Deposits	11,010	11,010
Total assets	11,797,064	10,393,899
Current liabilities:
Accounts payable	2,057,534	267,702
Accrued expenses	3,377,826	359,281
Current portion of notes payable	0	183,326
Total current liabilities	5,435,360	810,309
Accrued expenses – noncurrent	2,000,000	0
Note payable, net of current portion	0	14,738
Total liabilities	7,435,360	825,047
Commitments (Note 6)
Stockholders’ equity:
Preferred stock, $.01 par value: Authorized shares – 10,000,000 Series B convertible preferred stock, $1,000 stated value; -0- and 100 shares issued and outstanding at December 31, 2021 and 2020, respectively	0	76,095
Common stock, $.001 par value: Authorized shares – 600,000,000 Issued and outstanding shares – 6,381,541 and 3,834,095 at December 31, 2021 and 2020, respectively	6,382	3,834
Additional paid-in capital	68,731,220	55,294,504
Accumulated deficit	(64,375,898)	(45,805,581)
Total stockholders’ equity	4,361,704	9,568,852
Total liabilities and stockholders’ equity	$ 11,797,064	$ 10,393,899

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parentheticals) - $ / shares	Dec. 31, 2021	Dec. 31, 2020
Preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, authorized (in shares)	600,000,000	600,000,000
Common stock, issued (in shares)	6,381,541	3,834,095
Common stock, outstanding (in shares)	6,381,541	3,834,095
Series B Convertible Preferred Stock [Member]
Preferred stock, par value (in dollars per share)	$ 1,000	$ 1,000
Preferred stock, shares authorized (in shares)	10,000,000	10,000,000
Preferred stock, shares issued (in shares)	0	100
Preferred stock, shares outstanding (in shares)	0	100

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Grant and collaboration revenue	$ 385,501	$ 1,823,658
Operating expenses:
Research and development	15,554,171	2,444,459
General and administrative	3,577,153	2,196,014
Total operating expenses	19,131,324	4,640,473
Loss from operations	(18,745,823)	(2,816,815)
Other income (expense):
Interest income	4,736	2,271
Interest expense	(1,286)	(143,524)
Gain on debt extinguishment	172,056	0
Total other income (expense)	175,506	(141,253)
Net loss	$ (18,570,317)	$ (2,958,068)
Basic and diluted:
Net loss per common share (in dollars per share)	$ (3.04)	$ (2.14)
Weighted average shares outstanding (in shares)	6,099,933	1,383,829

Consolidated Statements of Chan

Consolidated Statements of Changes in Stockholders' Equity (Deficiency) - USD ($)	Warrant Issued for Technology License[Member]Preferred Stock [Member]	Warrant Issued for Technology License[Member]Common Stock [Member]	Warrant Issued for Technology License[Member]Additional Paid-in Capital [Member]	Warrant Issued for Technology License[Member]Retained Earnings [Member]	Warrant Issued for Technology License[Member]	Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Balance (in shares) at Dec. 31, 2019						2,486	14,992
Balance at Dec. 31, 2019						$ 1,932,433	$ 15	$ 39,340,509	$ (42,847,513)	$ (1,574,556)
Sale of convertible preferred stock for cash (in shares)						300	0
Sale of convertible preferred stock for cash						$ 300,000	$ 0	0	0	300,000
Conversion of preferred stock to common stock (in shares)						(2,686)	716,790
Conversion of preferred stock to common stock						$ (2,156,338)	$ 717	2,155,621	0	0
Warrants issued in bridge financing						$ 0	$ 0	457,833	0	457,833
Common stock issued (in shares)						0	286,902
Issuance of common stock upon warrant exercise						$ 0	$ 287	2,213	0	2,500
Issuance of common stock upon debenture conversion (in shares)						0	177,626
Issuance of common stock upon debenture conversion						$ 0	$ 177	569,340	0	$ 569,517
Common stock issued for cancellation of accrued compensation (in shares)						0	300,001			300,001
Issuance of common stock upon cancellation of accrued compensation						$ 0	$ 300	1,499,700	0	$ 1,500,000
Sale of common stock for cash (in shares)						0	2,310,000
Sale of common stock for cash						$ 0	$ 2,310	11,156,186	0	$ 11,158,496
Issuance of common stock for services (in shares)						0	26,581			26,581
Issuance of common stock for services						$ 0	$ 27	94,373	0	$ 94,400
Stock option expense								18,730		18,730
Roundup of shares following reverse stock split (in shares)						0	1,203
Roundup of shares following reverse stock split						$ 0	$ 1	(1)	0	0
Net loss						$ 0	$ 0	0	(2,958,068)	(2,958,068)
Balance (in shares) at Dec. 31, 2020						100	3,834,095
Balance at Dec. 31, 2020						$ 76,095	$ 3,834	55,294,504	(45,805,581)	9,568,852
Warrants issued in bridge financing	$ 0	$ 0	$ 209,825	$ 0	$ 209,825
Common stock issued (in shares)						0	889,739
Issuance of common stock upon warrant exercise						$ 0	$ 890	3,403,266	0	3,404,156
Sale of common stock for cash (in shares)						0	1,644,000
Sale of common stock for cash						$ 0	$ 1,644	9,407,276	0	$ 9,408,920
Issuance of common stock for services (in shares)						0	13,707			13,707
Issuance of common stock for services						$ 0	$ 14	71,827	0	$ 71,841
Stock option expense						0	0	269,427	0	269,427
Net loss						$ 0	$ 0	0	(18,570,317)	(18,570,317)
Repurchase of preferred stock (in shares)						(100)	0
Repurchase of preferred stock						$ (76,095)	$ 0	75,095	0	(1,000)
Balance (in shares) at Dec. 31, 2021						0	6,381,541
Balance at Dec. 31, 2021						$ 0	$ 6,382	$ 68,731,220	$ (64,375,898)	$ 4,361,704

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Cash flows from operating activities:
Net loss	$ (18,570,317)	$ (2,958,068)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	38,521	19,656
Debt discount amortization	0	124,185
Stock-based compensation expense	369,987	64,463
Warrant issued for technology license fee	209,825	0
Gain on debt extinguishment	(172,056)	0
Changes in assets and liabilities:
Grant funds and other receivables	133,657	(114,060)
Prepaid expenses and other current assets	(16,270)	(24,702)
Accounts payable and accrued expenses	6,810,233	137,956
Total adjustments	7,373,897	207,498
Net cash used in operating activities	(11,196,420)	(2,750,570)
Cash flows from investing activities:
Purchase of property and equipment	(47,718)	(156,791)
Net cash used in investing activities	(47,718)	(156,791)
Cash flows from financing activities:
Net proceeds from sale of common stock and warrants	9,408,920	11,158,496
Net proceeds from warrant exercises	3,404,156	2,500
Net proceeds from sale of preferred stock	0	300,000
Net proceeds from issuance of note payable	0	170,200
Net proceeds from bridge financing	0	888,500
Repurchase of preferred stock	(1,000)	0
Principal repayment of note payable	(27,864)	(11,880)
Net cash provided by financing activities	12,784,212	12,507,816
Net increase in cash and cash equivalents	1,540,074	9,600,455
Cash and cash equivalents at beginning of period	9,883,796	283,341
Cash and cash equivalents at end of period	$ 11,423,870	$ 9,883,796

Consolidated Statements of Ca_2

Consolidated Statements of Cash Flows (Parentheticals) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Shares issued (in shares)		716,790
Common stock issued for cancellation of accrued compensation (in shares)		300,001
Deferred compensation		$ 1,500,000
Paycheck Protection Program CARES Act [Member]
Extinguishment of debt	$ 172,056
Conversion from Convertible Debentures to Conversion Units [Member]
Shares issued upon conversion (in shares)		177,626
Convertible debentures		$ 1,200,000
Related accrued interest		$ 14,667
Stock Purchase Warrants First Issuance [Member]
Common stock issued (in shares)	149,705	36,902
Unit Warrants [Member]
Warrant issued (in shares)		300,001
Unit Warrants [Member] | Conversion from Convertible Debentures to Conversion Units [Member]
Pre-funded stock purchase warrants (in shares)		303,668
Pre-Funded Warrants [Member] | Conversion from Convertible Debentures to Conversion Units [Member]
Pre-funded stock purchase warrants (in shares)		126,042

Note 1 - Description of Busines

Note 1 - Description of Business and Recent Developments	12 Months Ended
	Dec. 31, 2021
Notes to Financial Statements
Nature of Operations [Text Block]	1. Description of Business and Recent Developments GeoVax Labs, Inc. (“GeoVax” or the “Company”), is a clinical-stage biotechnology company developing immunotherapies and vaccines against infectious diseases and cancers using novel vector vaccine platforms. GeoVax’s product pipeline includes ongoing human clinical trials in COVID- 19 GEO- CM04S1 November 2021, CM04S1 COH04S1 CM04S1, 2 GEO- CM04S1 2 CM04S1 19 2 2 14 first 19 19 In December 2021, 2 1/2 CM04S1, CM04S1 2 COH04S1 may 19 CM04S1 may Gedeptin License September 2021, 1/2 no not GeoVax is incorporated under the laws of the State of Delaware and our principal offices are located in the metropolitan Atlanta, Georgia area.

Note 2 - Summary of Significant

Note 2 - Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2021
Notes to Financial Statements
Significant Accounting Policies [Text Block]	2. Summary of Significant Accounting Policies Principles of Consolidation The accompanying consolidated financial statements include the accounts of GeoVax Labs, Inc. together with those of our wholly-owned subsidiary, GeoVax, Inc. All intercompany transactions have been eliminated in consolidation. Basis of Presentation On January 21, 2020, 1 September 25, 2020, 1 The accompanying consolidated financial statements have been prepared assuming that we will continue as a going concern, which contemplates realization of assets and the satisfaction of liabilities in the normal course of business for the twelve may We have funded our activities to date from sales of our equity securities, government grants and clinical trial assistance, and corporate and academic collaborations. We believe that our existing cash will be sufficient to continue our planned operations into the second 2023. may no Use of Estimates The preparation of financial statements in conformity with generally accepted accounting principles (GAAP) requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results may Cash and Cash Equivalents We consider all highly liquid investments with a maturity of three Fair Value of Financial Instruments and Concentration of Credit Risk Financial instruments that subject us to concentration of credit risk consist primarily of cash and cash equivalents, which are maintained by a high credit quality financial institution. The carrying values reported in the balance sheets for cash and cash equivalents approximate fair values. Property and Equipment Property and equipment are stated at cost, less accumulated depreciation and amortization. Expenditures for maintenance and repairs are charged to operations as incurred, while additions and improvements are capitalized. We calculate depreciation using the straight-line method over the estimated useful lives of the assets which range from three five We recognize leases in accordance with Financial Accounting Standards Board (FASB) Accounting Standards Update (ASU) No. 2016 02, Leases 2016 02 not 12 12 not Impairment of Long-Lived Assets We review long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not Accrued Expenses As part of the process of preparing our financial statements, we estimate expenses that we believe we have incurred, but have not third Net Loss Per Share Basic and diluted loss per common share are computed based on the weighted average number of common shares outstanding. Common share equivalents consist of common shares issuable upon conversion of convertible preferred stock, and upon exercise of stock options and stock purchase warrants. All common share equivalents are excluded from the computation of diluted loss per share since the effect would be anti-dilutive. The weighted average number of common share equivalents which were excluded from the computation of diluted loss per share, calculated using the treasury stock method, totaled 213,831 and 1,001,948 shares at December 31, 2021 2020, Revenue Recognition We recognize revenue in accordance with FASB Accounting Standards Update 2014 09, Revenue from Contracts with Customers 2014 09 606. five Grant revenue Research collaborations may third 2014 09 Research and Development Expense Research and development (R&D) expense primarily consists of costs incurred in the discovery, development, testing and manufacturing of our product candidates. These expenses consist primarily of (i) salaries, benefits, and stock-based compensation for personnel, (ii) laboratory supplies and facility-related expenses to conduct development, (iii) fees paid to third 2021, Patent Costs Our expenditures relating to obtaining and protecting patents are charged to expense when incurred and are included in general and administrative expense. Period-to-Period Comparisons Our operating results are expected to fluctuate for the foreseeable future. Therefore, period-to-period comparisons should not Income Taxes We account for income taxes using the liability method. Under this method, deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted rates in effect for the year in which temporary differences are expected to be recovered or settled. Deferred tax assets are reduced by a valuation allowance unless, in the opinion of management, it is more likely than not Stock-Based Compensation We account for stock-based transactions in which the Company receives services from employees, directors or others in exchange for equity instruments based on the fair value of the award at the grant date. Stock-based compensation cost for awards of common stock is estimated based on the price of the underlying common stock on the date of issuance. Stock-based compensation cost for stock options or warrants is estimated at the grant date based on each instrument’s fair value as calculated by the Black-Scholes option pricing model. We recognize stock-based compensation cost as expense ratably on a straight-line basis over the requisite service period for the award. See Note 7 Other Recent Accounting Pronouncements Except as discussed above, there have been no not

Note 3 - Property and Equipment

Note 3 - Property and Equipment	12 Months Ended
	Dec. 31, 2021
Notes to Financial Statements
Property, Plant and Equipment Disclosure [Text Block]	3. Property and Equipment Property and equipment as shown on the accompanying Consolidated Balance Sheets is composed of the following as of December 31, 2021 2020: 2021 2020 Equipment and furnishings $ 591,554 $ 543,836 Leasehold improvements 115,605 115,605 Total property and equipment 707,159 659,441 Accumulated depreciation and amortization (550,221 ) (511,700 ) Property and equipment, net $ 156,938 $ 147,741 Depreciation expense was $38,521 and $19,656 during the years ended December 31, 2021 2020,

Note 4 - Accrued Expenses

Note 4 - Accrued Expenses	12 Months Ended
	Dec. 31, 2021
Notes to Financial Statements
Accounts Payable and Accrued Liabilities Disclosure [Text Block]	4. Accrued Expenses Accrued expenses as shown on the accompanying Consolidated Balance Sheets is composed of the following as of December 31, 2021 2020: 2021 2020 Accrued license fees – current $ 3,000,000 $ - Accrued license fees – noncurrent 2,000,000 - Accrued payroll 269,000 279,696 Other accrued expenses 108,826 79,585 Total accrued expenses $ 5,377,826 $ 359,281

Note 5 - Debt

Note 5 - Debt	12 Months Ended
	Dec. 31, 2021
Notes to Financial Statements
Debt Disclosure [Text Block]	5. Debt GRA Note February 28, 2018, five May 2021, CARES Act Paycheck Protection Program Loan April 17, 2020, one May 2021, Convertible Debentures June 26 2020, 7, September 2020, Interest expense recorded for the years ended December 31, 2021 2019 2021 2020 GRA Note $ 633 $ 1,727 PPP Loan 653 1,203 Insurance premium financing costs - 1,743 Convertible debentures (including $124,185 of debt discount amortization) - 138,851 Total interest expense $ 1,286 $ 143,524

Note 6 - Commitments

Note 6 - Commitments	12 Months Ended
	Dec. 31, 2021
Notes to Financial Statements
Commitments Disclosure [Text Block]	6. Commitments Operating Lease We lease approximately 8,400 square feet of office and laboratory space pursuant to an operating lease which expires on December 31, 2022. December 31, 2021 2020 2022, may ninety License Agreements We have entered into license agreements with City of Hope, PNP Therapeutics, Inc., University of Alabama at Birmingham, Southern Research Institute, Emory University, and with the U.S. Department of Health and Human Services (HHS), as represented by National Institute of Allergy and Infectious Diseases (NIAID), an institute of the National Institutes of Health (NIH), for various technologies and patent rights associated with our product development activities. These agreements may 2022, 2023, 2024, 2025 2026. Other Commitments In the normal course of business, we enter into various firm purchase commitments related to production and testing of our vaccine, conduct of research studies, and other activities. As of December 31, 2021, 2022.

Note 7 - Stockholders' Equity

Note 7 - Stockholders' Equity	12 Months Ended
	Dec. 31, 2021
Notes to Financial Statements
Preferred Stock [Text Block]	7. Stockholders Equity Preferred Stock In June 2021, December 31, 2021, Common Stock 2020 September 29, 2020, “2020 2020 five From 2016 August 2020, 2020 Upon consummation of the 2020 2021 February 11, 2021, Warrant exercises 2021, 2020 2021, 2020, Other Common Stock Transactions 2021 2020 2020 Stock Option Plan We have a stock-based incentive plan (the “2020 may 2020 may not ten We use the Black-Scholes model for determining the grant date fair value of our stock option grants. This model utilizes certain information, such as the interest rate on a risk-free security with a term generally equivalent to the expected life of the option being valued and requires certain other assumptions, such as the expected amount of time an option will be outstanding until it is exercised or expired, to calculate the fair value of stock options granted. The significant assumptions we used in our fair value calculations were as follows: 2021 2020 Weighted average risk-free interest rates 1.43 % 0.69 % Expected dividend yield 0.0 % 0.0 % Expected life of option (in years) 7.0 7.0 Expected volatility 84.80 % 38.16 % A summary of stock option activity under the 2020 December 31, 2021, Number of Shares Weighted- Average Exercise Price Weighted- Average Remaining Contractual Term (yrs) Aggregate Intrinsic Value Outstanding at December 31, 2020 602,000 $ 2.79 Granted 360,300 3.82 Exercised - - Forfeited or expired - - Outstanding at December 31, 2021 962,300 $ 3.18 9.31 $ 499,660 Exercisable at December 31, 2021 200,661 $ 2.79 8.93 $ 166,549 The weighted-average grant date fair values of options granted during 2021 2020 December 31, 2021 2020 December 31, 2021, Stock Purchase Warrants Summary of Warrants Outstanding December 31, 2021. Warrant Description Number of Shares Exercise Price Expiration 2020 Warrants 120,000 5.00 Jun 2025 2020 Unit Warrants 2,396,631 5.00 Sep 2025 2020 Representative Warrants 128,000 5.50 Mar 2024 2021 Representative Warrants 72,000 6.875 Aug 2024 2021 Warrants 100,000 13.00 Sep 2026 Total Warrants Outstanding at December 31, 2021 2,816,631 Weighted-Average Exercise Price $ 5.35 Weighted-Average Remaining Life (in years) 3.7 2020 June 2020, five 2020 September 2020 2020 September 2020, 2020 2020 five 2021, 2020 September 2020, 2020 2021 February 2021, 2021 2021 September 2021, five Additional Stock-Based Compensation Expense In addition to stock-based compensation expense related to the 2020 Stock Options December 31, 2021 2020, December 31, 2021, 2022

Note 8 - Retirement Plan

Note 8 - Retirement Plan	12 Months Ended
	Dec. 31, 2021
Notes to Financial Statements
Retirement Benefits [Text Block]	8. Retirement Plan We participate in a multi-employer defined contribution retirement plan (the “401k third 401k December 31, 2021 2020 401k

Note 9 - Income Taxes

Note 9 - Income Taxes	12 Months Ended
	Dec. 31, 2021
Notes to Financial Statements
Income Tax Disclosure [Text Block]	9. Income Taxes At December 31, 2021, 2022 2037. 2022 2041 No 382 may may Deferred income taxes reflect the net effect of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Significant components of our deferred tax assets and liabilities included the following at December 31, 2021 2020: 2021 2020 Deferred tax assets: Net operating loss carryforward $ 18,449,694 $ 14,737,240 Research and development tax credit carryforward 1,566,293 1,189,110 Stock-based compensation expense 129,475 4,870 Accrued salaries 69,940 72,721 Total deferred tax assets 20,215,402 16,003,941 Deferred tax liabilities Depreciation 30,945 28,274 Net deferred tax assets 20,184,457 15,975,667 Valuation allowance (20,184,457 ) (15,975,667 ) Net deferred tax asset after reduction for valuation allowance $ -0- $ -0- We have established a full valuation allowance equal to the amount of our net deferred tax assets due to uncertainties with respect to our ability to generate sufficient taxable income to realize these assets in the future. A reconciliation of the income tax benefit on losses at the U.S. federal statutory rate to the reported income tax expense is as follows: 2021 2020 U.S. federal statutory rate applied to pretax loss $ (3,899,767 ) $ (621,194 ) Permanent differences - 65 Research and development credits (377,183 ) (66,574 ) Change in valuation allowance, net of expired items and other adjustments 4,276,950 687,703 Reported income tax expense $ -0- $ -0-

Note 10 - Grants and Collaborat

Note 10 - Grants and Collaboration Revenue	12 Months Ended
	Dec. 31, 2021
Notes to Financial Statements
Government Grants and Contracts [Text Block]	10. Grants and Collaboration Revenue We receive payments from government entities under our grants from the National Institute of Allergy and Infectious Diseases (NIAID) and from the U.S. Department of Defense in support of our vaccine research and development efforts. We record revenue associated with government grants as the reimbursable costs are incurred. During 2021 2020, December 31, 2021, 2022. 2020,

Note 11 - Subsequent Events

Note 11 - Subsequent Events	12 Months Ended
	Dec. 31, 2021
Notes to Financial Statements
Subsequent Events [Text Block]	11. Subsequent Events On January 19, 2022, five

Schedule II - Valuation and Qua

Schedule II - Valuation and Qualifying Accounts	12 Months Ended
	Dec. 31, 2021
Notes to Financial Statements
SEC Schedule, 12-09, Schedule of Valuation and Qualifying Accounts Disclosure [Text Block]	GEOVAX LABS, INC. SCHEDULE II VALUATION AND QUALIFYING ACCOUNTS For the Years Ended December 31, 2021 2020 Additions (Reductions) Description Balance at Beginning Of Period Charged to Costs and Expenses Charged to Other Accounts Deductions Balance at End Of Period Reserve Deducted in the Balance Sheet From the Asset to Which it Applies: Allowance for Deferred Tax Assets Year ended December 31, 2021 $ 15,975,667 $ 4,208,790 $ -0- $ -0- $ 20,184,457 Year ended December 31, 2020 $ 18,787,230 $ (2,811,563 ) $ -0- $ -0- $ 15,975,667

Significant Accounting Policies

Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2021
Accounting Policies [Abstract]
Consolidation, Policy [Policy Text Block]	Principles of Consolidation The accompanying consolidated financial statements include the accounts of GeoVax Labs, Inc. together with those of our wholly-owned subsidiary, GeoVax, Inc. All intercompany transactions have been eliminated in consolidation.
Basis of Accounting, Policy [Policy Text Block]	Basis of Presentation On January 21, 2020, 1 September 25, 2020, 1 The accompanying consolidated financial statements have been prepared assuming that we will continue as a going concern, which contemplates realization of assets and the satisfaction of liabilities in the normal course of business for the twelve may We have funded our activities to date from sales of our equity securities, government grants and clinical trial assistance, and corporate and academic collaborations. We believe that our existing cash will be sufficient to continue our planned operations into the second 2023. may no
Use of Estimates, Policy [Policy Text Block]	Use of Estimates The preparation of financial statements in conformity with generally accepted accounting principles (GAAP) requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results may
Cash and Cash Equivalents, Policy [Policy Text Block]	Cash and Cash Equivalents We consider all highly liquid investments with a maturity of three
Fair Value of Financial Instruments, Policy [Policy Text Block]	Fair Value of Financial Instruments and Concentration of Credit Risk Financial instruments that subject us to concentration of credit risk consist primarily of cash and cash equivalents, which are maintained by a high credit quality financial institution. The carrying values reported in the balance sheets for cash and cash equivalents approximate fair values.
Property, Plant and Equipment, Policy [Policy Text Block]	Property and Equipment Property and equipment are stated at cost, less accumulated depreciation and amortization. Expenditures for maintenance and repairs are charged to operations as incurred, while additions and improvements are capitalized. We calculate depreciation using the straight-line method over the estimated useful lives of the assets which range from three five We recognize leases in accordance with Financial Accounting Standards Board (FASB) Accounting Standards Update (ASU) No. 2016 02, Leases 2016 02 not 12 12 not
Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]	Impairment of Long-Lived Assets We review long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not
Accrued Liabilities [Policy Text Block]	Accrued Expenses As part of the process of preparing our financial statements, we estimate expenses that we believe we have incurred, but have not third
Earnings Per Share, Policy [Policy Text Block]	Net Loss Per Share Basic and diluted loss per common share are computed based on the weighted average number of common shares outstanding. Common share equivalents consist of common shares issuable upon conversion of convertible preferred stock, and upon exercise of stock options and stock purchase warrants. All common share equivalents are excluded from the computation of diluted loss per share since the effect would be anti-dilutive. The weighted average number of common share equivalents which were excluded from the computation of diluted loss per share, calculated using the treasury stock method, totaled 213,831 and 1,001,948 shares at December 31, 2021 2020,
Revenue from Contract with Customer [Policy Text Block]	Revenue Recognition We recognize revenue in accordance with FASB Accounting Standards Update 2014 09, Revenue from Contracts with Customers 2014 09 606. five Grant revenue Research collaborations may third 2014 09
Research and Development Expense, Policy [Policy Text Block]	Research and Development Expense Research and development (R&D) expense primarily consists of costs incurred in the discovery, development, testing and manufacturing of our product candidates. These expenses consist primarily of (i) salaries, benefits, and stock-based compensation for personnel, (ii) laboratory supplies and facility-related expenses to conduct development, (iii) fees paid to third 2021,
Intangible Assets, Finite-Lived, Policy [Policy Text Block]	Patent Costs Our expenditures relating to obtaining and protecting patents are charged to expense when incurred and are included in general and administrative expense.
Reclassification, Comparability Adjustment [Policy Text Block]	Period-to-Period Comparisons Our operating results are expected to fluctuate for the foreseeable future. Therefore, period-to-period comparisons should not
Income Tax, Policy [Policy Text Block]	Income Taxes We account for income taxes using the liability method. Under this method, deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted rates in effect for the year in which temporary differences are expected to be recovered or settled. Deferred tax assets are reduced by a valuation allowance unless, in the opinion of management, it is more likely than not
Share-based Payment Arrangement [Policy Text Block]	Stock-Based Compensation We account for stock-based transactions in which the Company receives services from employees, directors or others in exchange for equity instruments based on the fair value of the award at the grant date. Stock-based compensation cost for awards of common stock is estimated based on the price of the underlying common stock on the date of issuance. Stock-based compensation cost for stock options or warrants is estimated at the grant date based on each instrument’s fair value as calculated by the Black-Scholes option pricing model. We recognize stock-based compensation cost as expense ratably on a straight-line basis over the requisite service period for the award. See Note 7
New Accounting Pronouncements, Policy [Policy Text Block]	Other Recent Accounting Pronouncements Except as discussed above, there have been no not

Note 3 - Property and Equipme_2

Note 3 - Property and Equipment (Tables)	12 Months Ended
	Dec. 31, 2021
Notes Tables
Property, Plant and Equipment [Table Text Block]	2021 2020 Equipment and furnishings $ 591,554 $ 543,836 Leasehold improvements 115,605 115,605 Total property and equipment 707,159 659,441 Accumulated depreciation and amortization (550,221 ) (511,700 ) Property and equipment, net $ 156,938 $ 147,741

Note 4 - Accrued Expenses (Tabl

Note 4 - Accrued Expenses (Tables)	12 Months Ended
	Dec. 31, 2021
Notes Tables
Schedule of Accrued Liabilities [Table Text Block]	2021 2020 Accrued license fees – current $ 3,000,000 $ - Accrued license fees – noncurrent 2,000,000 - Accrued payroll 269,000 279,696 Other accrued expenses 108,826 79,585 Total accrued expenses $ 5,377,826 $ 359,281

Note 5 - Debt (Tables)

Note 5 - Debt (Tables)	12 Months Ended
	Dec. 31, 2021
Notes Tables
Interest Expense Disclosure [Table Text Block]	2021 2020 GRA Note $ 633 $ 1,727 PPP Loan 653 1,203 Insurance premium financing costs - 1,743 Convertible debentures (including $124,185 of debt discount amortization) - 138,851 Total interest expense $ 1,286 $ 143,524

Note 7 - Stockholders' Equity (

Note 7 - Stockholders' Equity (Tables)	12 Months Ended
	Dec. 31, 2021
Notes Tables
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	2021 2020 Weighted average risk-free interest rates 1.43 % 0.69 % Expected dividend yield 0.0 % 0.0 % Expected life of option (in years) 7.0 7.0 Expected volatility 84.80 % 38.16 %
Share-based Payment Arrangement, Option, Activity [Table Text Block]	Number of Shares Weighted- Average Exercise Price Weighted- Average Remaining Contractual Term (yrs) Aggregate Intrinsic Value Outstanding at December 31, 2020 602,000 $ 2.79 Granted 360,300 3.82 Exercised - - Forfeited or expired - - Outstanding at December 31, 2021 962,300 $ 3.18 9.31 $ 499,660 Exercisable at December 31, 2021 200,661 $ 2.79 8.93 $ 166,549
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	Warrant Description Number of Shares Exercise Price Expiration 2020 Warrants 120,000 5.00 Jun 2025 2020 Unit Warrants 2,396,631 5.00 Sep 2025 2020 Representative Warrants 128,000 5.50 Mar 2024 2021 Representative Warrants 72,000 6.875 Aug 2024 2021 Warrants 100,000 13.00 Sep 2026 Total Warrants Outstanding at December 31, 2021 2,816,631 Weighted-Average Exercise Price $ 5.35 Weighted-Average Remaining Life (in years) 3.7

Note 9 - Income Taxes (Tables)

Note 9 - Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2021
Notes Tables
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]	2021 2020 Deferred tax assets: Net operating loss carryforward $ 18,449,694 $ 14,737,240 Research and development tax credit carryforward 1,566,293 1,189,110 Stock-based compensation expense 129,475 4,870 Accrued salaries 69,940 72,721 Total deferred tax assets 20,215,402 16,003,941 Deferred tax liabilities Depreciation 30,945 28,274 Net deferred tax assets 20,184,457 15,975,667 Valuation allowance (20,184,457 ) (15,975,667 ) Net deferred tax asset after reduction for valuation allowance $ -0- $ -0-
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]	2021 2020 U.S. federal statutory rate applied to pretax loss $ (3,899,767 ) $ (621,194 ) Permanent differences - 65 Research and development credits (377,183 ) (66,574 ) Change in valuation allowance, net of expired items and other adjustments 4,276,950 687,703 Reported income tax expense $ -0- $ -0-

Schedule II - Valuation and Q_2

Schedule II - Valuation and Qualifying Accounts (Tables)	12 Months Ended
	Dec. 31, 2021
Notes Tables
Summary of Valuation Allowance [Table Text Block]	Additions (Reductions) Description Balance at Beginning Of Period Charged to Costs and Expenses Charged to Other Accounts Deductions Balance at End Of Period Reserve Deducted in the Balance Sheet From the Asset to Which it Applies: Allowance for Deferred Tax Assets Year ended December 31, 2021 $ 15,975,667 $ 4,208,790 $ -0- $ -0- $ 20,184,457 Year ended December 31, 2020 $ 18,787,230 $ (2,811,563 ) $ -0- $ -0- $ 15,975,667

Note 2 - Summary of Significa_2

Note 2 - Summary of Significant Accounting Policies (Details Textual)	Sep. 25, 2020	Jan. 21, 2020	Dec. 31, 2021USD ($)shares	Dec. 31, 2020USD ($)shares
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares) | shares			213,831	1,001,948
Research and Development Expense, Total			$ 15,554,171	$ 2,444,459
Upfront Fees for COH and PNP License[Member]
Research and Development Expense, Total			$ 10,513,825
Minimum [Member]
Property, Plant and Equipment, Useful Life (Year)			3 years
Maximum [Member]
Property, Plant and Equipment, Useful Life (Year)			5 years
Reverse Stock Split [Member]
Stockholders' Equity Note, Stock Split, Conversion Ratio	20	2,000

Note 3 - Property and Equipme_3

Note 3 - Property and Equipment (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Depreciation, Depletion and Amortization, Nonproduction, Total	$ 38,521	$ 19,656

Note 3 - Property and Equipme_4

Note 3 - Property and Equipment - Schedule of Property and Equipment (Details) - USD ($)	Dec. 31, 2021	Dec. 31, 2020
Property and equipment, gross	$ 707,159	$ 659,441
Accumulated depreciation and amortization	(550,221)	(511,700)
Property and equipment, net	156,938	147,741
Equipment and Furnishings [Member]
Property and equipment, gross	591,554	543,836
Leasehold Improvements [Member]
Property and equipment, gross	$ 115,605	$ 115,605

Note 4 - Accrued Expenses - Sch

Note 4 - Accrued Expenses - Schedule of Accrued Expenses (Details) - USD ($)	Dec. 31, 2021	Dec. 31, 2020
Accrued license fees – current	$ 3,000,000	$ 0
Accrued license fees – noncurrent	2,000,000	0
Accrued payroll	269,000	279,696
Other accrued expenses	108,826	79,585
Total accrued expenses	$ 5,377,826	$ 359,281

Note 5 - Debt (Details Textual)

Note 5 - Debt (Details Textual) - USD ($)	May 01, 2021	Jun. 26, 2020	Apr. 17, 2020	Feb. 28, 2018	May 31, 2021	Dec. 31, 2021	Dec. 31, 2020
Proceeds from Notes Payable, Total				$ 50,000		$ 0	$ 170,200
Repayments of Notes Payable						27,864	11,880
Gain (Loss) on Extinguishment of Debt, Total						$ 172,056	$ 0
Convertible Debentures [Member]
Debt Instrument, Face Amount		$ 1,200,000
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)		120,000
Proceeds from Convertible Debt, Gross		$ 1,050,000
Paycheck Protection Program CARES Act [Member]
Proceeds from Notes Payable, Total			$ 170,200
Extinguishment of Debt, Amount					$ 170,200
Gain (Loss) from Interest Forgiven					1,856
Gain (Loss) on Extinguishment of Debt, Total	$ 172,056
Senior Notes [Member]
Debt Instrument, Term (Year)				5 years
Debt Instrument, Interest Rate, Stated Percentage				5.00%
Repayments of Notes Payable					$ 22,737

Note 5 - Debt - Interest Expens

Note 5 - Debt - Interest Expense (Details) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
GRA Note	$ 1,286	$ 143,524
Senior Notes [Member]
GRA Note	633	1,727
Paycheck Protection Program CARES Act [Member]
GRA Note	653	1,203
Insurance Premium Financing Costs[Member]
GRA Note	0	1,743
Convertible Debt [Member]
GRA Note	$ 0	$ 138,851

Note 5 - Debt - Interest Expe_2

Note 5 - Debt - Interest Expense (Details) (Parentheticals) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Debt discount amortization	$ 0	$ 124,185

Note 6 - Commitments (Details T

Note 6 - Commitments (Details Textual)	12 Months Ended
	Dec. 31, 2021USD ($)	Dec. 31, 2020USD ($)	Sep. 30, 2021ft²
Licensing Agreement, Future Minimum Payments Receivable, Current	$ 174,000
Licensing Agreement, Future Minimum Payments Receivable, in Two Years	128,000
Licensing Agreement, Future Minimum Payments Receivable, in Three Years	128,000
Licensing Agreement, Future Minimum Payments Receivable, in Four Years	28,000
Licensing Agreement, Future Minimum Payments Receivable, in Five Years	28,000
Unrecorded Unconditional Purchase Obligation, Total	407,000
Office and Laboratory Lease Agreement [Member]
Area of Real Estate Property (Square Foot) | ft²			8,400
Operating Lease, Expense	166,242	$ 166,577
Lessee, Operating Lease, Liability, to be Paid, Year One	$ 176,356

Note 7 - Stockholders' Equity_2

Note 7 - Stockholders' Equity (Details Textual) - USD ($)	Feb. 11, 2021	Sep. 29, 2020	Dec. 31, 2021	Dec. 31, 2020	Sep. 30, 2021	Sep. 28, 2021	Jun. 01, 2021	Sep. 24, 2020	Jun. 26, 2020
Preferred Stock, Par or Stated Value Per Share (in dollars per share)			$ 0.01	$ 0.01
Proceeds from Issuance or Sale of Equity, Gross		$ 12,800,000
Proceeds from Issuance or Sale of Equity, Total		$ 11,200,000
Number of Common Stock Securities Called by Each Unit (in shares)		1
Deferred Compensation Liability Conversion to Equity, Amount		$ 1,500,000		$ 1,500,000
Deferred Compensation Liability Conversion to Equity, Conversion Price (in dollars per share)		$ 5
Stock Issued During Period, Shares, Cancellation of Accrued Compensation (in shares)		300,001		300,001
Stock Issued During Period, Shares, Conversion of Convertible Securities (in shares)		177,626
Stock Issued During Period, Shares, New Issues (in shares)	1,644,000
Stock Issued During Period, Value, New Issues	$ 10,300,000		$ 9,408,920	$ 11,158,496
Proceeds from Issuance of Common Stock	$ 9,400,000
Proceeds from Warrant Exercises			$ 3,404,156	$ 2,500
Stock Issued During Period, Shares, Issued for Services (in shares)			13,707	26,581
Conversion of Stock, Shares Issued (in shares)				716,790
Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent				110.00%
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year)				10 years
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share)			$ 2.87	$ 1.12
Prepaid Expense, Value of Stock Issued for Services During Period			$ 19,947
Expense Related To Consulting And Investment Banking Agreements [Member]
Share-based Payment Arrangement, Expense			100,560	$ 45,733
Share-based Payment Arrangement, Option [Member]
Share-based Payment Arrangement, Expense			269,427	$ 18,730
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total			$ 1,420,144
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)			2 years 2 months 12 days
Stock Incentive Plan 2020 [Member]
Common Stock, Capital Shares Reserved for Future Issuance (in shares)					1,500,000
Conversion of Series H, Series I, and Series J Preferred Stock into Common Stock [Member]
Conversion of Stock, Shares Issued (in shares)				716,790
Conversion from Convertible Debentures to Conversion Units [Member]
Debt Conversion, Converted Instrument, Principal and Interest, Amount		$ 1,214,667
Conversion Warrants [Member]
Class Of Warrant Or Right, Issued During Period (in shares)		2,560,000
Conversion Warrants [Member] | Conversion from Convertible Debentures to Conversion Units [Member]
Debt Conversion, Converted Instrument, Warrants or Options Issued (in shares)		303,668
Unit Warrant [Member]
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)		1
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)		$ 5	$ 5
Warrants and Rights Outstanding, Term (Year)		5 years
Class of Warrant or Right, Exercised During Period (in shares)			740,034
Proceeds from Warrant Exercises, Gross			$ 3,700,000
Proceeds from Warrant Exercises			$ 3,400,000
Stock Issued During Period, Shares, Warrants Exercised (in shares)			27,004
Pre-Funded Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)		1
Pre-Funded Warrants [Member] | Conversion from Convertible Debentures to Conversion Units [Member]
Debt Conversion, Converted Instrument, Warrants or Options Issued (in shares)		126,042		126,042
Management Warrant [Member]
Number of Warrants Called by Each Unit (in shares)		1
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)		300,001
Stock Purchase Warrants [Member]
Class of Warrant or Right, Exercised During Period (in shares)			215,672	54,557
Stock Issued During Period, Shares, Warrants Exercised (in shares)			149,705	36,902
June 2020 Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)		$ 5							$ 10
Warrants and Rights Outstanding, Term (Year)									5 years
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)									120,000
Conversion of Convertible Debenture [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)		303,668
Unit Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)		2,560,000
Unit Warrants [Member] | Conversion from Convertible Debentures to Conversion Units [Member]
Debt Conversion, Converted Instrument, Warrants or Options Issued (in shares)				303,668
Representative Warrants 2020 [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)			$ 5.50					$ 5.50
Warrants and Rights Outstanding, Term (Year)		42 months
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)		128,000
Representative Warrants 2021 [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)	$ 6.875		6.875
Warrants and Rights Outstanding, Term (Year)	42 months
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)	72,000
Warrants 2021 [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)			$ 13			$ 13
Warrants and Rights Outstanding, Term (Year)						5 years
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)						100,000
Series B Convertible Preferred Stock [Member]
Preferred Stock, Shares Outstanding, Ending Balance (in shares)			0	100			100
Preferred Stock, Par or Stated Value Per Share (in dollars per share)			$ 1,000	$ 1,000
Capital Units Tranche One [Member] | Capital Units [Member]
Number of Common Stock Securities Called by Each Unit (in shares)		1

Note 7 - Stockholders' Equity -

Note 7 - Stockholders' Equity - Significant Assumption Used in Fair Value Calculation (Details)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Weighted average risk-free interest rates	1.43%	0.69%
Expected dividend yield	0.00%	0.00%
Expected life of option (in years) (Year)	7 years	7 years
Expected volatility	84.80%	38.16%

Note 7 - Stockholders' Equity-

Note 7 - Stockholders' Equity- Stock Option Activity (Details)	12 Months Ended
	Dec. 31, 2021USD ($)$ / sharesshares
Outstanding (in shares)	602,000
Outstanding, weighted average exercise price (in dollars per share) | $ / shares	$ 2.79
Granted (in shares)	360,300
Granted, weighted average exercise price (in dollars per share) | $ / shares	$ 3.82
Exercised (in shares)	0
Exercised, weighted average exercise price (in dollars per share) | $ / shares	$ 0
Forfeited or expired (in shares)	0
Outstanding (in shares)	962,300
Outstanding, weighted average exercise price (in dollars per share) | $ / shares	$ 3.18
Outstanding, weighted average remaining contractual term (Year)	9 years 3 months 21 days
Outstanding, aggregate intrinsic value | $	$ 499,660
Exercisable (in shares)	200,661
Exercisable, weighted average exercise price (in dollars per share) | $ / shares	$ 2.79
Exercisable, weighted average remaining contractual term (Year)	8 years 11 months 4 days
Exercisable, aggregate intrinsic value | $	$ 166,549

Note 7 - Stockholders' Equity_3

Note 7 - Stockholders' Equity - Summary of Warrants Outstanding (Details) - $ / shares	Dec. 31, 2021	Sep. 28, 2021	Feb. 11, 2021	Sep. 29, 2020	Sep. 24, 2020
Number of warrants (in shares)	2,816,631
Weighted Average [Member]
Exercise price (in dollars per share)	$ 5.35
Warrants 2020 [Member]
Number of warrants (in shares)	120,000
Exercise price (in dollars per share)	$ 5
Unit Warrant [Member]
Number of warrants (in shares)	2,396,631
Exercise price (in dollars per share)	$ 5			$ 5
Weighted-Average Remaining Life (in years) (Year)				5 years
Representative Warrants 2020 [Member]
Number of warrants (in shares)	128,000
Exercise price (in dollars per share)	$ 5.50				$ 5.50
Weighted-Average Remaining Life (in years) (Year)				42 months
Representative Warrants 2021 [Member]
Number of warrants (in shares)	72,000
Exercise price (in dollars per share)	$ 6.875		$ 6.875
Weighted-Average Remaining Life (in years) (Year)			42 months
Warrants 2021 [Member]
Number of warrants (in shares)	100,000
Exercise price (in dollars per share)	$ 13	$ 13
Weighted-Average Remaining Life (in years) (Year)		5 years
Remaining Life on Warrants Outstanding[Member] | Weighted Average [Member]
Weighted-Average Remaining Life (in years) (Year)	3 years 8 months 12 days

Note 8 - Retirement Plan (Detai

Note 8 - Retirement Plan (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Defined Contribution Plan, Employer Discretionary Contribution Amount	$ 36,980	$ 27,511

Note 9 - Income Taxes (Details

Note 9 - Income Taxes (Details Textual) $ in Thousands	12 Months Ended
	Dec. 31, 2021USD ($)
Income Taxes Paid	$ 0
Research Tax Credit Carryforward [Member]
Tax Credit Carryforward, Amount	1,600
Domestic Tax Authority [Member]
Operating Loss Carryforwards, Total	75,200
Operating Loss Carryforwards, Subject to Expiration	$ 48,900

Note 9 - Income Taxes - Deferre

Note 9 - Income Taxes - Deferred Tax Assets and Liabilities (Details) - USD ($)	Dec. 31, 2021	Dec. 31, 2020
Net operating loss carryforward	$ 18,449,694	$ 14,737,240
Research and development tax credit carryforward	1,566,293	1,189,110
Stock-based compensation expense	129,475	4,870
Accrued salaries	69,940	72,721
Total deferred tax assets	20,215,402	16,003,941
Depreciation	30,945	28,274
Net deferred tax assets	20,184,457	15,975,667
Valuation allowance	(20,184,457)	(15,975,667)
Net deferred tax asset after reduction for valuation allowance	$ 0	$ 0

Note 9 - Income Taxes - Reconci

Note 9 - Income Taxes - Reconciliation of Income Tax Benefit (Details) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
U.S. federal statutory rate applied to pretax loss	$ (3,899,767)	$ (621,194)
Permanent differences	0	65
Research and development credits	(377,183)	(66,574)
Change in valuation allowance, net of expired items and other adjustments	4,276,950	687,703
Reported income tax expense	$ 0	$ 0

Note 10 - Grants and Collabor_2

Note 10 - Grants and Collaboration Revenue (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Revenue from Contract with Customer, Including Assessed Tax	$ 385,501	$ 1,823,658
Unused Grant Funds	81,526
NIH Grants [Member]
Revenue from Contract with Customer, Including Assessed Tax	$ 385,501	1,438,465
Research Agreements [Member]
Revenue from Contract with Customer, Including Assessed Tax		$ 385,193

Note 11 - Subsequent Events (De

Note 11 - Subsequent Events (Details Textual) - USD ($) $ / shares in Units, $ in Millions	Jan. 19, 2022	Feb. 11, 2021	Sep. 29, 2020
Stock Issued During Period, Shares, New Issues (in shares)		1,644,000
Proceeds from Issuance or Sale of Equity, Total			$ 11.2
Subsequent Event [Member] | Pre-Funded Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)	2,360,000
Subsequent Event [Member] | Warrants Issued in Private Placement [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)	3,067,484
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)	$ 3.26
Warrants and Rights Outstanding, Term (Year)	5 years
Subsequent Event [Member] | Private Placement [Member]
Stock Issued During Period, Shares, New Issues (in shares)	707,484
Proceeds from Issuance or Sale of Equity, Total	$ 9.2

Schedule II - Valuation and Q_3

Schedule II - Valuation and Qualifying Accounts (Details) - SEC Schedule, 12-09, Valuation Allowance, Deferred Tax Asset [Member] - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Balance at Beginning Of Period	$ 15,975,667	$ 18,787,230
Additions Charged to Costs and Expenses	4,208,790	(2,811,563)
Additions Charged to Other Accounts	0	0
Deductions	0	0
Balance at End Of Period	$ 20,184,457	$ 15,975,667